Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical Transplant for CGD Using Alemtuzumab, Busulfan, TBI, and Post-Transplant Cyclophosphamide
NCT03910452Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2019
- Primary completion
- Jun 2034
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic peripheral blood stem cell in chronic granulomatous disease (CGD), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Engraftment - Chimerism at 12 months. Started Oct 2019; status: active, not recruiting.
02
Drugs
allogeneic peripheral blood stem cell
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT03910452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910452.